ArticleJournal of inflammation research2025
Unveiling the Therapeutic Potential of Jiawei Jianpi Huoyu Formula in Ulcerative Colitis: A Multi-Strategies and Experimental Study Integrating Network Pharmacology, Machine Learning, and Mendelian Randomization.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.Journal of inflammation research · 2026Review
- Effects of Shenkang for chronic kidney disease: a propensity score matched with network pharmacology analysis.Renal failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. A modified traditional Chinese medicine (TCM) formula, "Jiawei Jianpi Huoyu Formula (JJHF)", has been reported to be effective in relieving UC symptoms, but its potential pharmacological components and targets remain unclear. Methods: This study employs an integrative approach combining network pharmacology, machine learning, molecular docking, Mendelian randomization (MR), and experimental validation to investigate the therapeutic mechanisms of JJHF in UC. Results: We identified 199 intersecting targets that were considered potential JJHF targets for treating UC. Network analysis revealed quercetin, luteolin, and kaempferol as key components modulating inflammatory pathways such as TNF and IL-6. Machine learning identified four core targets associated with UC progression, including glycogen synthase kinase 3 beta (GSK3B), vascular cell adhesion protein 1 (VCAM1), caspase-1 (CASP1), and heat shock protein family A member 5 (HSPA5). Molecular docking confirmed strong binding affinities between these targets and JJHF components, particularly β-sitosterol and HSPA5. In vitro experiments demonstrated that JJHF's efficacy in reducing LPS-induced inflammatory cytokines (IL-1β, TNF-α, MCP-1) and downregulating the expression of HSPA5, GSK3B, VCAM1, and CASP1 mRNA expression in RAW264.7 macrophages. In vivo, sixty mice were utilized to assess the efficacy of JJHF in DSS-induced colitis, where the JJHF alleviated colitis, improved colon length, disease activity index (DAI), and histopathology while suppressing pro-inflammatory cytokines. Notably, MR analysis established a causal link between elevated HSPA5 expression and UC risk (OR=5.639, p=0.040). Conclusion: These findings highlight the innovative application of MR in JJHF research and underscore its multi-component, multi-target mechanisms in UC treatment, particularly through anti-inflammatory pathways and modulation of HSPA5 signaling. This study lays a scientific foundation for the clinical application and mechanistic exploration of JJHF in managing UC, offering potential advantages over standard therapies like mesalazine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.